LOS ANGELES, June 4, 2004 (PRIMEZONE) -- Bio-Life Labs, Inc. (OTCBB:BLFE) announced today that to more accurately reflect the business of the Company following the recent merger, the Board of Directors has approved a change from the TecScan corporate name to Bio-Life Labs, Inc. Effective May 19, 2004 the new trading symbol for the Company's common stock on the OTC Bulletin Board is BLFE.
About Bio-Life
Bio-Life, Labs, Inc. is a research-driven biotechnology company focused on discovery, development, manufacturing, and commercialization of breakthrough treatments for cancer, diabetes mellitus, and hepatitis C. The Company's first product candidate, Carcinoderm, is a topical treatment that in the estimation of Management destroys skin cancer cells in patients diagnosed with Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma in a one-time application without harming surrounding healthy tissue.
Bio-Life labs, Inc. cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Bio-Life labs, Inc. that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Bio-Life labs, Inc.'s business including, without limitation, statements about: difficulties or delays in research, development, testing, obtaining regulatory approval, producing and marketing its technologies and products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; its ability to meet product development objectives; competition from other pharmaceutical or biotechnology companies; its ability to obtain additional financing to support its operations; its ability to attract and retain experienced scientists and management; as well as other risks detailed in Bio-Life labs, Inc.'s Securities and Exchange Commission filings. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Bio-Life labs, Inc. undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.